Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
moxifloxacin + dexamethasone (Alcon Inc.)
- Development stage
- Unknown
- Lead developer
- Alcon
- Modality
- Small Molecules
- Administration
- Topical, Otic
01
Overview
Moxidex is an investigational fixed-dose combination otic solution developed by Alcon Research for the treatment of acute otitis externa (AOE) and acute otitis media with otorrhea in patients with tympanostomy tubes (AOMT). The formulation contains moxifloxacin, a fourth-generation fluoroquinolone antibiotic, and dexamethasone, a potent synthetic glucocorticoid. Moxifloxacin exerts its antibacterial effect by inhibiting bacterial DNA gyrase and topoisomerase IV, enzymes essential for DNA replication, transcription, repair, and recombination. Dexamethasone provides anti-inflammatory activity by acting as an agonist at the glucocorticoid receptor, thereby reducing the inflammation, edema, and pain associated with ear infections. Moxidex was evaluated in Phase 3 clinical trials to demonstrate superior efficacy compared to its individual components and vehicle in resolving clinical signs and symptoms of otic infections.
- Brand names
- Moxidex
- Other names
- moxifloxacin/dexamethasone otic solution
02
Targets
GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on moxifloxacin + dexamethasone (Alcon Inc.).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on moxifloxacin + dexamethasone (Alcon Inc.).